The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
-
- Bryan E. Jones
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Patricia L. Brown-Augsburger
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Kizzmekia S. Corbett
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Kathryn Westendorf
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Julian Davies
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Thomas P. Cujec
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Christopher M. Wiethoff
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Jamie L. Blackbourne
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Beverly A. Heinz
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Denisa Foster
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Richard E. Higgs
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Deepa Balasubramaniam
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Lingshu Wang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Yi Zhang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Eun Sung Yang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Roza Bidshahri
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Lucas Kraft
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Yuri Hwang
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Stefanie Žentelis
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Kevin R. Jepson
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Rodrigo Goya
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Maia A. Smith
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- David W. Collins
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Samuel J. Hinshaw
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Sean A. Tycho
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Davide Pellacani
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Ping Xiang
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Krithika Muthuraman
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Solmaz Sobhanifar
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Marissa H. Piper
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Franz J. Triana
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Jorg Hendle
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Anna Pustilnik
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
-
- Andrew C. Adams
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Shawn J. Berens
- Eli Lilly and Company, Indianapolis, IN 46225, USA.
-
- Ralph S. Baric
- University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
-
- David R. Martinez
- University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
-
- Robert W. Cross
- Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
-
- Thomas W. Geisbert
- Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
-
- Viktoriya Borisevich
- Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
-
- Olubukola Abiona
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Hayley M. Belli
- Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Maren de Vries
- Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Adil Mohamed
- Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Meike Dittmann
- Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Marie I. Samanovic
- NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Mark J. Mulligan
- NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.
-
- Jory A. Goldsmith
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
-
- Ching-Lin Hsieh
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
-
- Nicole V. Johnson
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
-
- Daniel Wrapp
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
-
- Jason S. McLellan
- Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
-
- Bryan C. Barnhart
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Barney S. Graham
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- John R. Mascola
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
-
- Carl L. Hansen
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
-
- Ester Falconer
- AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
抄録
<jats:p>LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.</jats:p>
収録刊行物
-
- Science Translational Medicine
-
Science Translational Medicine 13 (593), eabf1906-, 2021-05-12
American Association for the Advancement of Science (AAAS)